Library
Sources and terminology
29 primary references and 32 glossary entries drawn from across the curriculum. Every clinical statement in this course traces back to something on this page.
- Executive summary of the Stages of Reproductive Aging Workshop +10 ↗Harlow et al., J Clin Endocrinol Metab 2012Reproductive Aging and the STRAW+10 Map →
- ESHRE Guideline: Premature Ovarian Insufficiency (2024 update) ↗ESHREReproductive Aging and the STRAW+10 Map →
- Menopause: diagnosis and management (NG23) ↗NICEReproductive Aging and the STRAW+10 Map →
- Duration of menopausal vasomotor symptoms over the menopause transition (SWAN) ↗Avis et al., JAMA Intern Med 2015Vasomotor Symptoms: KNDy Neurons and the Thermoneutral Zone →
- Fezolinetant for moderate-to-severe vasomotor symptoms (SKYLIGHT 2) ↗Johnson et al., J Clin Endocrinol Metab 2023Vasomotor Symptoms: KNDy Neurons and the Thermoneutral Zone →
- Elinzanetant for vasomotor symptoms (OASIS 1 and 2) ↗Pinkerton et al., JAMA 2024Vasomotor Symptoms: KNDy Neurons and the Thermoneutral Zone →
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality (WHI 18-year follow-up) ↗Manson et al., JAMA 2017Menopausal Hormone Therapy: Reading WHI Properly →
- Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE) ↗Hodis et al., NEJM 2016Menopausal Hormone Therapy: Reading WHI Properly →
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society ↗Menopause 2022Menopausal Hormone Therapy: Reading WHI Properly →
- Menopause: diagnosis and management (NG23) — prescribing ↗NICEPrescribing MHT: Routes, Regimens and Progestogen Choice →
- Hormone therapy and venous thromboembolism among postmenopausal women (ESTHER) ↗Canonico et al., Circulation 2007Prescribing MHT: Routes, Regimens and Progestogen Choice →
- Global Consensus Position Statement on the Use of Testosterone Therapy for Women ↗Davis et al., 2019Prescribing MHT: Routes, Regimens and Progestogen Choice →
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society ↗Menopause 2023Non-Hormonal Therapy for Vasomotor Symptoms →
- Efficacy and safety of fezolinetant (SKYLIGHT 1) ↗Lederman et al., Lancet 2023Non-Hormonal Therapy for Vasomotor Symptoms →
- Cognitive behavioural therapy for menopausal symptoms (MENOS trials) ↗Ayers et al., Menopause 2012Non-Hormonal Therapy for Vasomotor Symptoms →
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society ↗Menopause 2020Genitourinary Syndrome of Menopause →
- A controlled trial of intravaginal estriol in postmenopausal women with recurrent UTI ↗Raz & Stamm, NEJM 1993Genitourinary Syndrome of Menopause →
- FDA Safety Communication: Energy-based devices for vaginal 'rejuvenation' ↗FDAGenitourinary Syndrome of Menopause →
- Bone mineral density changes during the menopause transition (SWAN) ↗Greendale et al., J Bone Miner Res 2012Bone Loss, Fracture Risk and the Sarcopenia Overlap →
- Effects of Estrogen Plus Progestin on Risk of Fracture (WHI) ↗Cauley et al., JAMA 2003Bone Loss, Fracture Risk and the Sarcopenia Overlap →
- Discontinuation of denosumab and associated vertebral fracture risk ↗Cummings et al., J Bone Miner Res 2018Bone Loss, Fracture Risk and the Sarcopenia Overlap →
- Menopause Transition and Cardiovascular Disease Risk: AHA Scientific Statement ↗El Khoudary et al., Circulation 2020Cardiometabolic Change After 50 →
- Adiposity changes across the menopause transition (SWAN) ↗Greendale et al., JCI Insight 2019Cardiometabolic Change After 50 →
- Longitudinal changes in cognition in the menopausal transition (SWAN) ↗Greendale et al., Neurology 2009Brain Fog, Mood and Sleep →
- Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms ↗Gordon et al., JAMA Psychiatry 2018Brain Fog, Mood and Sleep →
- Conjugated Equine Estrogens and Incidence of Probable Dementia (WHIMS) ↗Shumaker et al., JAMA 2003Brain Fog, Mood and Sleep →
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society ↗Menopause 2022The Menopause Consultation: Equity, Risk Communication and Review →
- Duration of menopausal vasomotor symptoms — racial/ethnic differences (SWAN) ↗Avis et al., JAMA Intern Med 2015The Menopause Consultation: Equity, Risk Communication and Review →
- Simple tools for understanding risks: from innumeracy to insight ↗Gigerenzer & Edwards, BMJ 2003The Menopause Consultation: Equity, Risk Communication and Review →